Persantine, Dipyridamole News

CombinatoRx, Incorporated today announced the results of a 12 month knee osteoarthritis Phase 2 extension trial for Synavivea at the American College of Rheumatology 2009 Annual Meeting in Philadelphia.

Early secondary prevention with Aggrenox is at least as effective and safe as initial treatment with ASA 100 mg alone after an ischaemic stroke or transient ischaemic attack .

Updated May 19, 2006 Antiplatelet Drugs Drugs that reduce the formation or inhibit the action of chemicals that promote the activation and aggregation of platelets, blood components important for the clotting of blood.

In the area of secondary prevention as well - guarding against renewed events in patients who already suffered from a stroke or a TIA - Professor Ferro points to important new research: "In this patient population, the direct comparison between Clopidogrel and the combination of aspirin with extended release Dipyridamole did not reveal any ...

Jun 12, 2009 - CombinatoRx, Incorporated today announced the presentation of full data on Synavive Phase 2 knee osteoarthritis trial at EULAR 2009, the Annual European Congress of Rheumatology in Copenhagen on June 12, 2009.

Jun 3, 2009 - CombinatoRx, Incorporated today announced positive results from a Phase 1 clinical study evaluating the relative bioavailability of an oral once-daily aligned-release formulation of SynaviveTM .

There are a number of commonly used medications to treat and prevent strokes. Most, however, are used to prevent.

A new study, led by a University of Iowa researcher, shows for the first time that the anti-clotting drug dipyridamole combined with aspirin delays the initial failure of arteriovenous vascular access grafts used in hemodialysis for patients with end-stage kidney disease.

From the Department of Pharmacology-Toxicology , Anesthesiology , Nuclear Medicine , Cardiologie , and Internal Medicine , Radboud University Nijmegen Medical Centre, The Netherlands.

A new drug combination may keep grafts working better for dialysis patients and boost their chances at a healthier life.

Bradley S. Dixon, M.D., Gerald J. Beck, Ph.D., Miguel A. Vazquez, M.D., Arthur Greenberg, M.D., James A. Delmez, M.D., Michael Allon, M.D., Laura M. Dember, M.D., Jonathan Himmelfarb, M.D., Jennifer J. Gassman, Ph.D., Tom Greene, Ph.D., Milena K. Radeva, M.S., Ingemar J. Davidson, M.D., T. Alp Ikizler, M.D., Gregory L. Braden, M.D., Andrew Z.

A combination of aspirin and the anti-clotting drug dipyridamole reduces blockages and extends the useful life of new artery-vein access grafts used for kidney dialysis, new research has found.

Aspirin therapy does not appear to significantly reduce cardiovascular events in patients with peripheral artery disease , according to a study in the May 13 Journal of the American Medical Association .

Clinician's Corner Aspirin for the Prevention of Cardiovascular Events in Patients With Peripheral Artery Disease A Meta-analysis of Randomized Trials Jeffrey S. Berger, MD, MS ; Mori J. Krantz, MD ; John M. Kittelson, PhD ; William R. Hiatt, MD JAMA.

OBJECTIVES: To determine the effects of adjuvant drug treatment on the patency of fistulae and grafts in patients with ESRD who are undergoing haemodialysis by assessing the number of thrombotic episodes.

Stroke. 2009;40:1941 Published online before print November 26, 2008, doi: 10.1161/STROKEAHA.108.541854 Emerging Therapies PRoFESS Kennedy R. Lees, MD From the Faculty of Medicine, University of Glasgow, Department of Medicine and Therapeutics, Western Infirmary, Glasgow, UK.